Lab test for a new Merkel cell cancer treatment
Part of Cancer, Skin clinical trials.
This trial is testing a lab method to see if a specific type of immunotherapy can work against Merkel cell carcinoma. It may help find new treatment options for people with this skin cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with Merkel cell carcinoma of the skin
- You are currently receiving or have recently completed treatment for your cancer, or are being monitored for it
- You are not taking part in any other clinical trial at the same time
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how people with Merkel cell carcinoma, a rare skin cancer, take part in clinical trials. By joining, you help researchers understand how to make trials easier for patients like you.
This study looks for cancer cells in your blood before and after surgery (and possibly radiation) to learn more about your cancer and how it responds to treatment. Participation involves giving blood samples, which may help doctors understand your disease better.
This trial tests an experimental vaccine (IFx-Hu2.0) followed by the immunotherapy drug pembrolizumab in people with advanced Merkel cell carcinoma who have not been treated with checkpoint inhibitors before. The goal is to see if this combination helps shrink or control the cancer.
This study looks at how insurance covers immunotherapy given before surgery for certain skin cancers. It includes people with Merkel cell, mucosal melanoma, basal cell, or other rare skin cancers who are planning to have surgery.
This trial tests a new combination for people with advanced Merkel cell carcinoma (MCC), a rare skin cancer. It combines the immunotherapy drug pembrolizumab with standard chemotherapy (cisplatin or carboplatin plus etoposide). The goal is to see if this combination shrinks or controls the cancer better than chemotherapy alone.
This trial tests a combination of two immunotherapy drugs, nivolumab and relatlimab, before surgery for Merkel cell carcinoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Hear when a new Merkel Cell Carcinoma of Skin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.